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Background: Despite its wide acceptance as a treatment for canine chronic enteropathies, the macrolide antibiotic
tylosin lacks official oral dosage recommendations. Not even textbooks share consensus about the dose; daily
recommendations vary from 25 to 80 mg/kg and dosing intervals from one to three times daily.
The objective of this prospective, single-blinded, two-arm parallel, clinical field trial was to determine whether doses
of 5 mg/kg or 15 mg/kg tylosin administered orally once daily for seven days would have a similar effect on fecal
consistency in diarrhea relapses to that of a 25 mg/kg dose of tylosin administered once daily for seven days, a
dosage that has proved effective in controlling canine tylosin-responsive diarrhea (TRD). A further objective was to
compare the efficacy of the 5 mg/kg and 15 mg/kg tylosin dosages. Fifteen client-owned dogs diagnosed with TRD
that had responded to a dose of 25 mg/kg tylosin once daily for seven days were enrolled in the study. After a
relapse of diarrhea the dogs were allocated into two groups receiving tylosin orally in doses of either 5 mg/kg or
15 mg/kg once daily for seven days. The owners were blinded to the dosage. The elimination of diarrhea was the
main criterion in assessing treatment success. The mean fecal consistency score of the last three treatment days for
all dosages, including 25 mg/kg, as evaluated by the owners according to a standardized fecal scoring system,
served as the primary outcome measures.
Results: All eight dogs responded to the 5 mg/kg dose, and six of seven dogs responded to the 15 mg/kg dose.
The mean fecal consistency scores at the 25 mg/kg tylosin dosage were no significantly different from scores at the
5 mg/kg or 15 mg/kg tylosin dosages (P = 0.672, P = 0.345).
Conclusions: Interestingly, 14/15 (93%) of the dogs responding to a dose of 25 mg/kg tylosin once daily for seven
days also responded to the lower dosages at diarrhea relapse. The data indicate that a suitable dose of tylosin for
treating diarrhea relapse in canine TRD could be as low as 5 mg/kg once daily for seven days.
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Tylosin, a member of the macrolide group of antibiotics, is
widely used in the treatment of canine chronic diarrhea of
unknown etiologies [1,2]. Currently, oral tylosin treatment
is not approved for the treatment of canine enteritis, but it
may be prescribed as an ex tempore drug, dispensed by the
pharmacy on request. Consequently, no official recommen-
dations are available for the oral dosage regimen in dogs,
and the literature shows that individual authors’ recom-
mended dosages differ.
In 1976, Van Kruiningen drew attention to the usefulness
of tylosin in treating enterocolitis in dogs in a study about
the clinical efficacy of tylosin in canine inflammatory bowel
disease [3]. This study comprised 27 dogs receiving a daily
oral dosage of tylosin between 11–200 mg/kg. The dosing
interval was twice daily, and the duration of treatment var-
ied from one week to five years. Two decades later, a case–
control study involved seven pet dogs with secondary
chronic diarrhea due to naturally occurring exocrine pan-
creatic insufficiency. The dogs received tylosin for 5–7 days
at a dose of 15 mg/kg twice daily as an adjunctive medica-
tion to the pancreatic enzyme [4]. In 2005, Westermarck
et al. introduced the term tylosin-responsive diarrhea
(TRD) in dogs in a case series involving nine client-owned
dogs suffering from recurrent diarrhea and responding to
tylosin at a dose of 6–16 mg/kg once daily for two weeks
[5]. Characteristic of TRD was that the dogs with recurrent
diarrhea, for which no underlying cause could be found,
usually responded to tylosin within a few days. The stool
remained normal as long as treatment continued, but diar-
rhea recurred in many dogs within weeks of discontinuing
the treatment. After initiating a repeated course, however,
the dogs’ response to tylosin was as good as the initial treat-
ment, even after several treatments.
A recent randomized controlled trial of the effect of
tylosin on fecal consistency in dogs with recurrent diar-
rhea revealed that tylosin proved significantly more ef-
fective than placebo. At a dose of 25 mg/kg once daily
for seven days, tylosin proved effective in controlling
diarrhea in 20 client-owned dogs [6].
However, despite the wide use and acceptance of tylo-
sin in the treatment of chronic enteropathies in dogs, a
clear consensus about the dosage regimen is lacking. In
textbooks, the dose recommendations for tylosin in dogs
with chronic diarrhea vary considerably, with daily dos-
ages ranging from 25 to 80 mg/kg, and dosing intervals
from one to three times daily [2,7,8]. These textbooks
contain little information about the original source of
this information. To date, no published dosage deter-
mination studies are available on the oral treatment of
dogs with chronic diarrhea by tylosin.
Therefore, the primary objective of the current study
was to determine whether tylosin doses of 5 mg/kg or
15 mg/kg administered orally once daily for seven dayshave a similar effect on the fecal consistency in diarrhea
relapses to that of 25 mg/kg dose of tylosin once
daily for seven days, a dosage that has proved effect-
ive in controlling canine TRD. A further objective
was to compare the efficacy of the 5 mg/kg and
15 mg/kg dosages.
Secondary objectives were to assess the recurrence
rate and the time to recurrence of diarrhea at a tylosin
dosage of 25 mg/kg once daily over a seven-day treat-
ment duration. Further objectives were to investigate the
influence of the three different tylosin dosages on the
time to the cessation of diarrhea.
Methods
Trial design, compliance and ethics approval
This trial was designed according the guidelines of
evidence-based medicine [9] and reported utilizing the
Consolidated Standards of Reporting Trials (CON-
SORT) [10-13]. The study design is a prospective,
single-blinded, two-arm parallel clinical dosage deter-
mination field trial. The study complied with the
European Economic Community Guideline on the dem-
onstration of efficacy for veterinary medicinal products
containing antimicrobial substances. Both the Ethics
Committee for Animal Experiments of the University of
Helsinki in Finland and the National Animal Experi-
ment Board in Finland approved the study protocol.
The owners provided their written informed consent in
which they agreed to participate with their dog.
Study population, inclusion and exclusion criteria
This study was conducted at the Small Animal Teaching
Hospital, Faculty of Veterinary Medicine, University of
Helsinki, Finland. The study population was recruited from
the patient material of a placebo-controlled, randomized,
double-blinded, prospective clinical trial on the effective-
ness of oral tylosin in treating recurrent diarrhea in dogs,
that was conducted just prior to this current dosage deter-
mination trial [6]. Dogs were considered eligible for the oral
tylosin dosage determination trial if they responded to a
tylosin treatment at a dosage of 25 mg/kg once daily for
seven days in the aforementioned trial. Inclusion criteria
were that the dogs were at least six months old and had
been suffering from recurrent diarrhea responding to
tylosin treatment. They were not allowed to have received
systemic corticosteroids, nonsteroidal anti-inflammatory
drugs, or antibiotics other than tylosin in the 90 days pre-
ceding the tylosin dosage determination trial. Lactating
bitches were excluded, as were dogs with evidence of sys-
temic or organ-related disease that could secondarily cause
diarrhea.
The dogs underwent an initial examination prior to
enrollment in the tylosin effectiveness trial to ensure
that they met the selection criteria. In brief, the initial
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ical examination, blood samples for a complete blood
count and serum biochemical profile, urinalysis, fecal
analysis for endoparasites and enteropathogenic bacteria,
and gastroduodenoscopy with mucosal biopsies from the
duodenum. The protocol and the results of the initial
examination have been published previously [6].
Outcome measures
The primary objective of the current trial was to assess
whether daily doses of 5 mg/kg or 15 mg/kg tylosin at a
once daily dosing interval for seven days would have similar
effects on the fecal consistency in diarrhea relapses to that
of an initial dose of 25 mg/kg tylosin once daily for seven
days in these dogs, a dosage that has proved effective in
controlling canine TRD [6]. Further to assess whether the
tylosin dose 5 mg/kg was as effective as the 15 mg/kg dose.
To evaluate this, the elimination of diarrhea served as the
main criterion. The elimination of diarrhea was fulfilled
when noting that on three consecutive days the fecal score
for each of the dog’s feces was and remained three or less.
A mean fecal consistency score assigned during the last
three days of the seven-day treatment period served as the
primary outcome measure. To determine the mean fecal
consistency score, the owners evaluated and recorded
throughout the study the consistency of each of their
dog’s stool according to a standardized fecal scoring
system previously established by Moxham [14]. This
kind of fecal scoring system has proved useful in
evaluating treatment success in diarrhea patients
[5,6,15-17]. In brief, the fecal scoring system is based
on a nine-point scale, consisting of scores from one
to five, with half-point intervals. To ensure uniformity
in the fecal consistency scoring, it comprises both a
verbal description and a visual picture for each of the
fecal consistency scores. Scores 1 and 1.5 represented
feces of a hard and dry consistency. Scores 2 and 2.5
indicated well-formed feces that left no mark when
picked up. A score of 3 represented feces of a slightly
moist consistency, whereas score 3.5 represented feces
of a moist consistency, but which still had some def-
inite form. Scores 4 through 5 described feces of poor
consistency.
To evaluate whether the tylosin dosage was effective, the
investigator calculated a mean fecal consistency score of
the scores assigned for each of the dog’s feces during the
last three days of the seven-day treatment period based on
the owner’s records. A responder was defined as having a
mean fecal consistency score of three or less; a non-
responder had a score of more than three. The owners were
unaware of these definitions.
Secondary outcome measures were defined in order to
evaluate the recurrence rate and the time to recurrence of
diarrhea at a 25 mg/kg dosage of tylosin. The recurrence ofdiarrhea was defined as when the dog’s feces had a
consistency score of at least four on the scale for at least
two consecutive defecations. Further secondary outcome
measures were defined to assess the influence of the three
different tylosin dosages (5, 15 and 25 mg/kg) on the time
of ceasing of diarrhea. The day on which the diarrhea
ceased was defined as the day of the treatment period on
which the fecal score for each of the dog’s feces was and
remained three or less.
Interventions
When assessing the dogs’ eligibility for this present dos-
age determination trial all dogs had diarrhea and began
their tylosin treatment at a dose of 25 mg/kg once daily
for seven days. The dog owners evaluated and recorded
the consistency of each of their dogs’ feces. On day
seven of the treatment period each dog underwent a
physical examination and its fecal consistency records
were collected. The investigator recorded the day on
which the dog’s diarrhea ceased and calculated a mean
fecal consistency score for each dog over the last three
days of the treatment period at a tylosin dosage of
25 mg/kg; the dogs defined as responders were deemed
eligible to participate in the dosage determination trial.
Treatment at 25 mg/kg tylosin was then discontinued
for the participating dogs and a follow-up period of up
to two months served to determine whether the diarrhea
recurred. No additional changes were permitted in the
dog’s feeding management or medication. Upon meeting
the criteria for the recurrence of diarrhea (fecal score ≥ 4
for at least two consecutive defecations) each dog under-
went a physical examination, during which the investiga-
tor also assessed and confirmed the fecal consistency by
rectal palpation. The dogs then received tylosin (Tylosin
tartrate 120 mg and 240 mg tablets, University Phar-
macy, Helsinki, Finland; equivalent to 100 mg and
200 mg tylosin) once daily for seven days in doses of ei-
ther 5 mg/kg or 15 mg/kg.
During the seven-day treatment period, the owners
continued evaluating each of their dog’s stools and
recorded its fecal consistency according to the guide-
lines. On day three, the investigator phoned the owner
to assure whether the clinical condition of the dog met
the criteria of the humane endpoint of the study and
whether the dog had to be released from the study and
treated accordingly. A humane endpoint was defined as
the point at which the dog’s clinical condition was poor
and it suffered from excessive diarrhea. On day seven,
the dog underwent a second physical examination, in-
cluding rectal palpation and an evaluation of the dog’s
fecal consistency. The fecal consistency records were
collected, and a mean fecal consistency score was calcu-
lated for each dog based on the last three days of the
treatment period at the 5 mg/kg or 15 mg/kg dosages.
Kilpinen et al. Acta Veterinaria Scandinavica 2014, 56:43 Page 4 of 8
http://www.actavetscand.com/content/56/1/43Allocation to treatment groups
After the onset of diarrhea within the two-month
follow-up period the dogs received an ascending study
number denoting the order in which the diarrhea ran-
domly recurred. The investigator then assigned the dogs
in a 1:1 ratio to two different dosage groups - either
5 mg/kg or 15 mg/kg - receiving tylosin orally once daily
for seven days. All dogs with odd study numbers were
assigned to the 5 mg/kg dosage group, and those with
even study numbers to the 15 mg/kg dosage group.
Blinding
The study was single-blinded and thus open to the in-
vestigator but blinded for the dog owner. The blinding
procedure was carried out by labeling the 120 mg tylosin
tartrate tablet bottles as “Tylosin tart. S” and the 240 mg
tylosin tartrate tablet bottles as “Tylosin tart. V”. The
tablets were visually identical.
Statistical methods
Descriptive statistics were used to summarize the data.
The Shapiro-Wilk test served to determine whether the
data were normally distributed; non-parametric data
were expressed as median and range. The Wilcoxon
signed rank test was used for non-parametric data to
compare the mean fecal consistency scores of the last
three days of the treatment period at the 25 mg/kg tylo-
sin dosage to the scores at the 15 mg/kg and 5 mg/kg
tylosin dosages. The Mann–Whitney U test was used to
examine differences between the mean fecal consistency
scores in the 5 mg/kg and 15 mg/kg tylosin dosage
groups. To evaluate the effect of each dosage on the
time until the diarrhea ceased, the Wilcoxon signed rank
test and the Mann–Whitney U test were used. The level
of statistical significance was set at P < 0.05; all statistical
analyses were performed with a commercially available
statistical software system (SPSS 18.0 for Windows).
Results
Participant flow and follow-up
Between October 2006 and May 2008, 20 client-owned
dogs responding to 25 mg/kg tylosin once daily for the
seven day treatment in the tylosin effectiveness trial [6]
were deemed eligible to participate in the present tylosin
dosage determination trial. One owner declined to partici-
pate with the dog for personal reasons, and two dogs were
excluded due to other concurrent medications that violated
the inclusion criteria. A total of 15 of 17 dogs relapsed and
diarrhea recurred within the two-month follow up period.
The results of the enrollment, allocation and response to
the two different tylosin dosages appear in Figure 1. It is
noteworthy that in treating their recurrent diarrhea, 14 of
15 dogs (93%) responding to a dose of 25 mg/kg tylosin
once daily also responded to the lesser dosages of 5 mg/kgor 15 mg/kg once daily for seven days. No adverse events
or side effects were recorded at any of the dosages in any of
the dogs. No deviations from the study protocol occurred
during the trial, and no dog had to be released from the
study due to excessive diarrhea or poor clinical condition.
Baseline data
The 15 dogs included in the prospective treatment trial
consisted of 12 different breeds: Golden Retriever (n =
3), German Shepherd (n = 2), and one of each of the fol-
lowing breeds (n = 1): Pumi, Rough Collie, Miniature
Schnauzer, Kromfohrländer, Doberman Pinscher, Border
Collie, German Shorthaired Pointer, Nova Scotia Duck-
Tolling Retriever, Old English Sheepdog, and mixed
breed. The dogs’ ages at the time of enrollment ranged
from seven months to four years and three months (me-
dian three years and eleven months). The weight of the
dogs at the time of enrollment ranged from 10 kg to
37.5 kg (median 25.2 kg). The study population included
nine intact males and six females, three of which were
intact.
Primary outcomes
Figure 2 shows the mean fecal consistency scores
assigned during the last three days of the treatment
period for each dog participating in the trial at tylosin
doses of 5 mg/kg (n = 8), 15 mg/kg (n = 7), and 25 mg/
kg (n = 15). Figure 3 shows the minimum and maximum,
the upper and lower quartiles, interquartile range and
the median of the mean fecal consistency scores at all
three tylosin dosages. The median of the mean fecal
consistency scores from the last three days of the treatment
period in the dogs receiving tylosin at the 25 mg/kg dosage
was 2.5 (95% confidence interval, 2.32; 2.65). In the dogs
receiving tylosin at the 15 mg/kg dosage, the median of the
mean fecal consistency scores from the last three days
of the treatment period was likewise 2.5 (95% confidence
interval, 2.10; 3.36). The median of the mean fecal
consistency scores from the last three days of the treatment
period in the dogs receiving 5 mg/kg tylosin was 2.63 (95%
confidence interval, 2.36; 2.82). The mean fecal consistency
scores for the 25 mg/kg dosage of tylosin showed no signifi-
cant difference from scores for the 15 mg/kg or 5 mg/kg
dosages of tylosin (Wilcoxon signed rank test, P = 0.345,
P = 0.672). Nor was the difference in the mean fecal
consistency scores between the dogs receiving 15 mg/kg
tylosin and those receiving 5 mg/kg tylosin significant
(Mann–Whitney U test, asymptotic P = 0.370 and exact,
not corrected for ties P = 0.397).
Secondary outcomes
At a dosage of 25 mg/kg tylosin and a treatment dur-
ation of seven days, 15 of 17 dogs relapsed, and diarrhea
recurred within the two-month follow-up period on a
Figure 1 Flowchart of the trial. Flowchart of the results of the study enrollment, the allocation to treatment groups, and the response to the
two different tylosin dosages.
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currence rate of 88%.
The day on which the diarrhea ceased in the dogs when
receiving the 25 mg/kg dosage of tylosin (n = 15) ranged
from days 1 to 5 (median day 3; 95% confidence interval,
2.20; 3.40). At the 15 mg/kg dosage of tylosin (n = 7), the
day on which diarrhea ceased ranged from days 2 to 5 (me-
dian day 2; 95% confidence interval, 1.68; 3.82) of the treat-
ment period, and at the 5 mg/kg dosage of tylosin (n = 8)
from days 1 to 5 (median day 2.5; 95% confidence interval,
1.40; 3.94). The number of days until the diarrhea ceased in
the dogs receiving 5 mg/kg tylosin compared to those re-
ceiving 15 mg/kg tylosin was not statistically significantly
different (Mann–Whitney U test, asymptotic P = 0.835).
Discussion
This study was conducted to evaluate the efficacy of two
low dose oral tylosin treatment regimens to control the
relapse of diarrhea in dogs suffering from TRD. Our re-
sults showed that 14 of the 15 dogs (93%) suffering fromrecurrent diarrhea that previously responded to oral
tylosin therapy at a dose of 25 mg/kg once daily for
seven days, responded to the lower doses of 5 mg/kg
and 15 mg/kg once daily for seven days after diarrhea re-
lapse. These data indicate that a suitable daily oral dose
of tylosin for the treatment of diarrhea relapses in canine
TRD may thus far be less than the current recommenda-
tions in textbooks, which vary from 25 to 80 mg/kg
[2,7,8]. The limitations of this study were its rather small
sample size, as well as lack of randomization and con-
trols. Nevertheless, our results are in agreement with
those of a previous TRD study in which dog owners re-
duced the tylosin dose for their dogs as low as possible
(6–16 mg/kg per day) while maintaining their dogs’
health [5]. In both the aforementioned and the present
studies, however, all dogs had previously received several
oral tylosin treatments, so whether the efficacy would re-
main the same had the dog initially received tylosin at
low dosages remains uncertain. The groups receiving
5 mg/kg and 15 mg/kg tylosin were not independent of
Figure 2 Mean fecal consistency scores per dog. Mean fecal consistency scores at dosages of 25 mg/kg (n = 15), 15 mg/kg (n = 7), and 5 mg/kg
(n = 8) tylosin per dog assessed during the last three days of the seven-day treatment period.
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was carried out to investigate whether the mean fecal
consistency scores after the low dose treatments for
diarrhea relapse were similar to the scores at the initial
treatment and to compare only the treatment outcomes,
not its efficacy.
In the present study, one dog failed to respond to the
15 mg/kg once daily dosage, but did respond the 25 mg/kg
once daily dosage, possibly because this time the cause of
diarrhea in this dog may have differed. Since the owners de-
clined further diagnostic investigations in this case, the rea-
sons for the non-response remain uncertain.Figure 3 Box and whisker plots of the mean fecal consistency scores.
during the last three days of the seven-day treatment period at tylosin dos
limits of the box represent the 25th and 75th percentile values, the line with
the range. The black line indicates the cut-off value for a responder, set atAlthough pharmacokinetic studies have explored the
intramuscular and intravenous administration of tylosin in
dogs [18], studies on per oral administration are lacking.
Consequently, the dosing interval of per oral administration
remains unknown. Individual authors’ recommendations in
textbooks for the dosing interval of tylosin differ, ranging
from one to three times daily [2,7,8]. Our data show that a
once daily dosing interval is sufficient to stop diarrhea in
14/15 (93%) of the participating dogs during the treatment
period. This finding is consistent with those of earlier re-
ports on TRD in which a once-daily dosing interval proved
successful in controlling diarrhea in dogs with recurrentBox and whisker plots of the mean fecal consistency scores assessed
ages of 25 mg/kg (n = 15), 15 mg/kg (n = 7) and 5 mg/kg (n = 8). The
in the box represents the median values and the whiskers represent
a score of 3 on the mean fecal consistency score scale.
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interval is unnecessary in the treatment of diarrhea relapses
in TRD dogs. A once daily dosing makes the treatment cost
effective and more convenient for both the dog and the
owner.
Controversy also surrounds recommendations regarding
the duration of tylosin therapy in chronic enteropathies in
dogs. So far, recommendations for the duration of antibiotic
treatment in antibiotic-responsive diarrhea can range up to
six weeks, because premature cessation of treatment could
lead to relapse [1]. However, to the best of our knowledge,
no studies have yet investigated whether the treatment dur-
ation affects the recurrence rate. All of the dogs in this
present trial received tylosin for seven days at a dosage of
25 mg/kg before it was terminated. During the two month
follow-up 88% of the dogs relapsed. This is a higher recur-
rence rate than the one in our previous study, where diar-
rhea recurred in only 43.3% of the dogs investigated [6]. In
the aforementioned study, the duration of tylosin treatment
varied between the dogs. However, the high prevalence of
recurrence is in accordance with that of an earlier report
on TRD in which the low dosage tylosin treatment lasted
for at least six weeks. When the treatment was terminated,
the diarrhea recurred within 30 days in 85.7% of the dogs
[5]. Since an at least six-week tylosin course in TRD dogs
has not lead to smaller relapse rates than a seven-day
course, we conclude that a seven-day treatment period may
prove sufficient in the treatment of TRD in dogs. One limi-
tation of this study was that we were unable to follow the
dogs beyond the end of this trial to determine whether,
after receiving the low dosages, they showed signs of diar-
rhea relapse and whether the time interval between the ces-
sation of treatment and the relapse of clinical signs
depended on the dose or duration of the treatment. Add-
itional studies are warranted to further assess the effect of
treatment duration on diarrhea relapse.
At a dosage of 25 mg/kg tylosin and treatment dur-
ation of seven days diarrhea recurred in the dogs of this
trial on a median of day 9, which is in accordance with a
former study on TRD where at tylosin dosages varying
individually from 6 to 16 mg/kg, the diarrhea reappeared
on a median day of 7 [5].
Until now, some have suggested that in dogs with
antibiotic-responsive diarrhea who have shown a subopti-
mal response, the antibiotic should be changed after the
first two weeks [1]. In the present study the diarrhea ceased
in all dogs by day five of the tylosin treatment. The diarrhea
ceased in the dogs receiving 5, 15 and 25 mg/kg tylosin on
a median day of 2.5, 2 and 3, respectively. This result falls
within the same time frame as those published in earlier
studies on TRD [5,15] and indicates that in the absence of a
response after a few days of tylosin treatment, the treatment
should be terminated and further diagnostics introduced as
soon as possible. In small animal practice the uncritical useof antibiotics, including tylosin, contributes to the develop-
ment of resistant intestinal bacterial flora which also poses
a risk to public health. Thus, until alternative treatment op-
tions are found, one should aim to restrict the usage of
tylosin in chronic enteropathies in dogs when systemic dis-
orders have been ruled out and, despite thorough investiga-
tions, no other underlying primary intestinal disorder is
evident.
Conclusions
In conclusion, our results indicate that a suitable oral
dosage of tylosin in the treatment of diarrhea relapses in
canine tylosin-responsive diarrhea could be as low as
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